急性髓系白血病的可测量残留病检测
综述讨论急性髓系白血病(AML)完全缓解后可测量残留病(MRD)检测的技术现状,指出多种基于免疫表型或细胞遗传学/分子异常的方法各有优劣,阳性结果与白血病复发风险较高相关,但缺乏随机试验证明特定干预可降低复发风险,常规临床应用需进一步标准化。
要点
- AML的MRD检测方法包括免疫表型、细胞遗传学和分子异常检测,各有优缺点。
- 多个时间点MRD阳性与复发风险较高相关,即使校正其他预后变量后仍存在。
- 尚无MRD检测对复发预测具有完美敏感性和特异性,假阳性和假阴性率较高。
核心结论
- AML的MRD检测已取得实质性进展,但仍有许多工作要做。
- 缺乏 convincing 证据表明特定干预可降低MRD阳性者的复发风险,需在随机试验中验证。
- MRD检测的常规临床应用需要进一步优化和标准化/统一检测平台及结果报告。
研究设计与样本
- 综述,讨论AML完全缓解后MRD检测的技术现状、临床意义及局限性。
主要发现
- 许多研究报道,在AML治疗期间不同时间点MRD检测阳性者与MRD阴性者相比,即使校正其他预后和预测变量后,白血病复发风险更高。
- 尚无MRD检测在队列或个体水平对复发预测具有完美敏感性和特异性,假阳性和假阴性率较高。
- MRD检测结果与复发风险的相关性已引起对MRD结果指导治疗干预的兴趣。
临床怎么用
- 原文未据此给出推荐。
局限性
- 尚无MRD检测对复发预测具有完美敏感性和特异性,假阳性和假阴性率较高。
- 缺乏 convincing 证据表明特定干预可降低MRD阳性者的复发风险,需在随机试验中验证。
- MRD检测的常规临床应用需要进一步优化和标准化/统一检测平台及结果报告。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
There is considerable interest in developing techniques to detect and/or quantify remaining leukaemia cells termed measurable or, less precisely, minimal residual disease (MRD) in persons with acute myeloid leukaemia (AML) in complete remission defined by cytomorphological criteria. An important reason for AML MRD-testing is the possibility of estimating the likelihood (and timing) of leukaemia relapse. A perfect MRD-test would precisely quantify leukaemia cells biologically able and likely to cause leukaemia relapse within a defined interval. AML is genetically diverse and there is currently no uniform approach to detecting such cells. Several technologies focused on immune phenotype or cytogenetic and/or molecular abnormalities have been developed, each with advantages and disadvantages. Many studies report a positive MRD-test at diverse time points during AML therapy identifies persons with a higher risk of leukaemia relapse compared with those with a negative MRD-test even after adjusting for other prognostic and predictive variables. No MRD-test in AML has perfect sensitivity and specificity for relapse prediction at the cohort- or subject levels and there are substantial rates of false-positive and -negative tests. Despite these limitations, correlations between MRD-test results and relapse risk have generated interest in MRD-test result-directed therapy interventions. However, convincing proof that a specific intervention will reduce relapse risk in persons with a positive MRD-test is lacking and needs testing in randomized trials. Routine clinical use of MRD-testing requires further refinements and standardization/harmonization of assay platforms and results reporting. Such data are needed to determine whether results of MRD-testing can be used as a surrogate end point in AML therapy trials. This could make drug-testing more efficient and accelerate regulatory approvals. Although MRD-testing in AML has advanced substantially, much remains to be done.
引用
- Hourigan CS, Gale RP, Gormley NJ, et al. Measurable residual disease testing in acute myeloid leukaemia. Leukemia. 2017. PMID: 28386105. doi:10.1038/leu.2017.113
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。